FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016362016> ?p ?o ?g. }

• W3016362016 endingPage "3577" @default.
• W3016362016 startingPage "3565" @default.
• W3016362016 abstract "Cytomegalovirus (CMV) antigens occur in glioblastoma but not in normal brains, making them desirable immunologic targets.Highly functional autologous polyclonal CMV pp65-specific T cells from patients with glioblastoma were numerically expanded under good manufacturing practice compliant conditions and administered after 3 weeks of lymphodepleting dose-dense temozolomide (100 mg/m2) treatment. The phase I component used a 3+3 design, ascending through four dose levels (5 × 106-1 × 108 cells). Treatment occurred every 6 weeks for four cycles. In vivo persistence and effector function of CMV-specific T cells was determined by dextramer staining and multiparameter flow cytometry in serially sampled peripheral blood and in the tumor microenvironment.We screened 65 patients; 41 were seropositive for CMV; 25 underwent leukapheresis; and 20 completed ≥1 cycle. No dose-limiting toxicities were observed. Radiographic response was complete in 1 patient, partial in 2. Median progression-free survival (PFS) time was 1.3 months [95% confidence interval (CI), 0-8.3 months]; 6-month PFS was 19% (95% CI, 7%-52%); and median overall survival time was 12 months (95% CI, 6 months to not reached). Repeated infusions of CMV-T cells paralleled significant increases in circulating CMV+ CD8+ T cells, but cytokine production showing effector activity was suppressed, especially from T cells obtained directly from glioblastomas.Adoptive infusion of CMV-specific T cells after lymphodepletion with dose-dense temozolomide was well tolerated. But apparently CMV seropositivity does not guarantee tumor susceptibility to CMV-specific T cells, suggesting heterogeneity in CMV antigen expression. Moreover, effector function of these T cells was attenuated, indicating a requirement for further T-cell modulation to prevent their dysfunction before conducting large-scale clinical studies." @default.
• W3016362016 created "2020-04-24" @default.
• W3016362016 creator A5005282702 @default.
• W3016362016 creator A5007244861 @default.
• W3016362016 creator A5007445074 @default.
• W3016362016 creator A5008633199 @default.
• W3016362016 creator A5011213468 @default.
• W3016362016 creator A5012403937 @default.
• W3016362016 creator A5013307500 @default.
• W3016362016 creator A5017578103 @default.
• W3016362016 creator A5019540454 @default.
• W3016362016 creator A5021624182 @default.
• W3016362016 creator A5024476694 @default.
• W3016362016 creator A5026241338 @default.
• W3016362016 creator A5036347055 @default.
• W3016362016 creator A5038172006 @default.
• W3016362016 creator A5045061146 @default.
• W3016362016 creator A5045738854 @default.
• W3016362016 creator A5054514877 @default.
• W3016362016 creator A5054825595 @default.
• W3016362016 creator A5055074099 @default.
• W3016362016 creator A5055885795 @default.
• W3016362016 creator A5061272107 @default.
• W3016362016 creator A5071489703 @default.
• W3016362016 creator A5077658566 @default.
• W3016362016 creator A5079081497 @default.
• W3016362016 creator A5091806633 @default.
• W3016362016 date "2020-07-15" @default.
• W3016362016 modified "2023-10-17" @default.
• W3016362016 title "Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial" @default.
• W3016362016 cites W1967684158 @default.
• W3016362016 cites W1979072449 @default.
• W3016362016 cites W1996322297 @default.
• W3016362016 cites W2009607549 @default.
• W3016362016 cites W2013637325 @default.
• W3016362016 cites W2024505394 @default.
• W3016362016 cites W2033118453 @default.
• W3016362016 cites W2052491055 @default.
• W3016362016 cites W2070212505 @default.
• W3016362016 cites W2081758137 @default.
• W3016362016 cites W2092335024 @default.
• W3016362016 cites W2103212167 @default.
• W3016362016 cites W2103849595 @default.
• W3016362016 cites W2105350040 @default.
• W3016362016 cites W2111137187 @default.
• W3016362016 cites W2114701172 @default.
• W3016362016 cites W2116687125 @default.
• W3016362016 cites W2131480973 @default.
• W3016362016 cites W2135947790 @default.
• W3016362016 cites W2137605317 @default.
• W3016362016 cites W2137930630 @default.
• W3016362016 cites W2148923175 @default.
• W3016362016 cites W2162643152 @default.
• W3016362016 cites W2315098267 @default.
• W3016362016 cites W2398751720 @default.
• W3016362016 cites W2765633257 @default.
• W3016362016 cites W2790035192 @default.
• W3016362016 cites W2887361912 @default.
• W3016362016 cites W2913510435 @default.
• W3016362016 doi "https://doi.org/10.1158/1078-0432.ccr-20-0176" @default.
• W3016362016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32299815" @default.
• W3016362016 hasPublicationYear "2020" @default.
• W3016362016 type Work @default.
• W3016362016 sameAs 3016362016 @default.
• W3016362016 citedByCount "27" @default.
• W3016362016 countsByYear W30163620162020 @default.
• W3016362016 countsByYear W30163620162021 @default.
• W3016362016 countsByYear W30163620162022 @default.
• W3016362016 countsByYear W30163620162023 @default.
• W3016362016 crossrefType "journal-article" @default.
• W3016362016 hasAuthorship W3016362016A5005282702 @default.
• W3016362016 hasAuthorship W3016362016A5007244861 @default.
• W3016362016 hasAuthorship W3016362016A5007445074 @default.
• W3016362016 hasAuthorship W3016362016A5008633199 @default.
• W3016362016 hasAuthorship W3016362016A5011213468 @default.
• W3016362016 hasAuthorship W3016362016A5012403937 @default.
• W3016362016 hasAuthorship W3016362016A5013307500 @default.
• W3016362016 hasAuthorship W3016362016A5017578103 @default.
• W3016362016 hasAuthorship W3016362016A5019540454 @default.
• W3016362016 hasAuthorship W3016362016A5021624182 @default.
• W3016362016 hasAuthorship W3016362016A5024476694 @default.
• W3016362016 hasAuthorship W3016362016A5026241338 @default.
• W3016362016 hasAuthorship W3016362016A5036347055 @default.
• W3016362016 hasAuthorship W3016362016A5038172006 @default.
• W3016362016 hasAuthorship W3016362016A5045061146 @default.
• W3016362016 hasAuthorship W3016362016A5045738854 @default.
• W3016362016 hasAuthorship W3016362016A5054514877 @default.
• W3016362016 hasAuthorship W3016362016A5054825595 @default.
• W3016362016 hasAuthorship W3016362016A5055074099 @default.
• W3016362016 hasAuthorship W3016362016A5055885795 @default.
• W3016362016 hasAuthorship W3016362016A5061272107 @default.
• W3016362016 hasAuthorship W3016362016A5071489703 @default.
• W3016362016 hasAuthorship W3016362016A5077658566 @default.
• W3016362016 hasAuthorship W3016362016A5079081497 @default.
• W3016362016 hasAuthorship W3016362016A5091806633 @default.
• W3016362016 hasBestOaLocation W30163620162 @default.
• W3016362016 hasConcept C10205521 @default.
• W3016362016 hasConcept C126322002 @default.

• next